12:00 AM
Jul 26, 2010
 |  BC Week In Review  |  Clinical News  |  Regulatory

Tysabri natalizumab regulatory update

Biogen Idec updated the U.S. label for autoimmune drug Tysabri natalizumab to warn that the risk of progressive multifocal leukoencephalopathy (PML) increases in patients with prior immunosuppressant use and that the increased...

Read the full 139 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >